Session 8 – Combating Pandemics (B)
Date: 23 July (Thursday) 14:00 – 15:30 (GMT+8)
Venue: 701EF, 7F, TaiNEX2 / Online event platform
Richeal M Cline is the Global Head of Quality & Regulatory Affairs since November 2019. In this role, Richeal reports to the CEO of Roche Diagnostics and is responsible for Quality, Regulatory Compliance, Regulatory Affairs and Regulatory Policy globally. She leads an organization of 1,000 employees across 15 sites located in Switzerland, Germany, Spain, USA, China and South Africa.
Prior to her role, she served as the Vice President and General Manager of Roche Singapore Technical Operations, and led a biologics production plant with over 500 staff responsible for producing oncology and ophthalmology drugs.
Richeal joined Roche in 1997 as a Scientist in Branchburg, NJ. As part of the Boehringer Mannheim integration, she relocated to Indianapolis, IN in 1999 and there she held various positions of increase responsibility in the areas of Operations and Quality in the Roche Centralized and Point of Care Solutions Business Area. In 2011, Richeal returned to the Branchburg site as the VP of Quality for Roche Molecular Diagnostic. In this role, she was a member of the Diagnostics Quality and Regulatory Leadership Team, the Roche Molecular Diagnostics Leadership Team and the Roche Molecular Diagnostics Lifecycle Committee. Richeal assumed the position of VP of Global Operations for Roche Molecular Diagnostic in 2013. In this role, she continued to be a member of the Roche Molecular Diagnostics Leadership Team and the Roche Molecular Diagnostics Lifecycle Committee and joined the Global Operations Leadership Team. She led four manufacturing facilities with a staff of 750 in the US and Switzerland responsible for the global supply of Roche Molecular Diagnostics products. She was also actively involved in the acquisition of two start-up companies and their integration in to Roche.
Originally, from Ireland, Richeal attended university in the United States receiving a Bachelor’s Degree in Biology, a Master’s Degree in Clinical Chemistry and a Master’s in Business Administration.
Speech title & Synopsis
The value of diagnostics has been elevated globally during the COVID-19 pandemic. How has Roche, the world’s leading IVD company responded to this pandemic? This presentation will cover the development of the first commercial test for COVID-19, an antibody test and other diagnostics solutions available to support patients and healthcare providers during this pandemic.
To develop two assays in record time does not happen without careful planning, great science and exceptional people. Many questions will be answered during the course of the presentation such as